Actively Recruiting

Age: 40Years - 80Years
All Genders
Healthy Volunteers
ID06582472

Early Retinal Neurodegeneration As Risk Factor, Biomarker and Pharmacological Target of Diabetic Retinopathy

Led by IRCCS Ospedale San Raffaele · Updated on 2024-09-03

180

Participants Needed

2

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating diabetic retinopathy (DR), a leading cause of blindness among working-age adults, focusing on early retinal neurodegeneration as a possible risk factor and biomarker for the disease. This observational study aims to clarify whether nerve cell damage in the retina contributes to later vascular problems seen in DR, which could open new avenues for treatment. The study includes two parts: a longitudinal follow-up of type 2 diabetes patients without DR, and a cross-sectional comparison of patients with long-standing diabetes with and without DR. The study involves detailed eye examinations and sample collections using advanced imaging techniques such as Optical Coherence Tomography (OCT), OCT Angiography (OCT-A), and Dynamic Vessel Analyzer (DVA). Procedures include confocal microscopy of the cornea, tear and blood sample collection for biomarker analysis, and conjunctival impression cytology. The longitudinal study will follow 120 participants (90 diabetic patients and 30 healthy controls) over 24 months with visits every six months. The cross-sectional study will include 60 participants with diabetes for over 20 years undergoing a single evaluation. Participants will undergo periodic ophthalmological assessments and laboratory tests to monitor retinal changes and inflammation markers. Researchers will analyze these data to understand the relationship between early neurodegeneration and diabetic retinopathy development. The study measures include imaging assessments, confocal microscopy, blood and tear sample analyses, with monitoring over two years for the longitudinal group. This comprehensive approach aims to identify early signs of DR and better understand its progression, with participant involvement lasting up to two years.

CONDITIONS

Brief Title

Early Retinal Neurodegeneration As Risk Factor, Biomarker and Pharmacological Target of Diabetic Retinopathy

Who Can Participate

Age: 40Years - 80Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Participant is willing and able to give informed consent for participation in the trial
  • Male or Female, aged 40 - 80 years
  • In good general health or diagnosed with type 2 diabetes for less than 10 years without clinical signs of retinopathy and other diabetic complications (longitudinal study patients)
  • HbA1c level 7% or greater (longitudinal study patients and cross-sectional study participants)
  • In good general health without diagnosis of type 2 diabetes (longitudinal study healthy controls)
  • Diagnosis of type 2 diabetes for longer than 20 years with or without clinical signs of retinopathy and other diabetic complications (cross-sectional study)
Not Eligible

You will not qualify if you...

  • Presence of retinal or systemic diseases other than diabetes
  • High blood pressure (BP values greater than 140/90 mm Hg)
  • Anemia (hematocrit less than 35%)
  • Smoking
  • Previous laser treatment
  • Pregnancy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - Up to 24 months

Participants undergo ophthalmological examinations, imaging assessments, confocal analysis of the cornea, Dynamic Vessel Analyzer measurements, tear sampling, and blood sampling to observe retinal neurodegeneration and vascular changes associated with diabetic retinopathy.

Visits at baseline, month 6, month 12, month 18, and month 24 for longitudinal study participants; 1 visit for cross-sectional study participants

Trial Site Locations

Total: 2 locations

1

Irccs Ospedale San Raffaele

Milan, Italy/milan, Italy, 20132

Actively Recruiting

2

IRCCS Ospedale San Raffaele _O.U. Ophthalmology

Milan, Italy, Italy, 20123

Actively Recruiting

Loading map...

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

4

Similar Trials

Randomized, Double-blind Study Comparing Ranibizumab 10mg/ml...

Diabetic Macular Edema

Actively Recruiting

1 location

A Phase 1b Open-Label, Multiple Ascending Dose Study of the ...

Diabetic Macular Edema

Actively Recruiting

2 locations

A Phase II Randomized, Double-Masked, Placebo-Controlled Stu...

Diabetic Retinopathy

Actively Recruiting

26 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here